Halozyme Therapeutics (HALO) News Today $61.39 +1.17 (+1.94%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Quinn Opportunity Partners LLC Acquires New Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Quinn Opportunity Partners LLC bought a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 12,500 shares of the biopharmaceutical company's stock,April 14 at 6:25 AM | marketbeat.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Wellington Management Group LLPWellington Management Group LLP reduced its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 12.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 57,370 shares of the biopharmaceutical companyApril 14 at 3:38 AM | marketbeat.comKennedy Capital Management LLC Purchases 29,484 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)Kennedy Capital Management LLC raised its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 8.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 394,026 shares of the biopharmaceutApril 12 at 8:55 AM | marketbeat.comCerity Partners LLC Reduces Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Cerity Partners LLC cut its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 2.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 334,852 shares of the biopharmaceutical company's stoApril 12 at 5:44 AM | marketbeat.comBiotech Stock Bounces From Support, Shows Relative Strength Amid Volatile MarketApril 11 at 5:01 PM | investors.comArgenx, Halozyme win FDA nod for Vyvgart Hytrulo prefilled syringeApril 11 at 9:13 AM | msn.comFederated Hermes Inc. Sells 322,415 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)Federated Hermes Inc. decreased its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 45.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 389,393 shares of the biopharmaceutical company'sApril 11 at 5:44 AM | marketbeat.comAviva PLC Acquires 38,765 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)Aviva PLC raised its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 39.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 137,413 shares of the biopharmaceutical company's stock after acquiring an aApril 11 at 5:17 AM | marketbeat.comHalozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating PolyneuropathyApril 10, 2025 | prnewswire.comRep. Gilbert Ray Cisneros, Jr. Sells Off Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)Representative Gilbert Ray Cisneros, Jr. (D-California) recently sold shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO). In a filing disclosed on April 07th, the Representative disclosed that they had sold between $1,001 and $15,000 in Halozyme Therapeutics stock on March 24th. The trade occurredApril 10, 2025 | marketbeat.comJ&J, Halozyme get EU nod for Darzalex SC to treat multiple myelomaApril 9, 2025 | msn.comEuropean Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant EligibilityApril 9, 2025 | prnewswire.comEuropean Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant EligibilityApril 9, 2025 | prnewswire.comCIBC Private Wealth Group LLC Trims Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)CIBC Private Wealth Group LLC decreased its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 99.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,053 shares of the biopharmaceutical company's stocApril 9, 2025 | marketbeat.comEC approves subcutaneous RYBREVANT in combination with LAZCLUZEApril 8, 2025 | markets.businessinsider.comJ&J, Halozyme win EU nod for injectable Rybrevant in lung cancerApril 8, 2025 | msn.com2Xideas AG Boosts Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)2Xideas AG raised its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 24.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 379,240 shares of the biopharmaceutical company's stApril 8, 2025 | marketbeat.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by California Public Employees Retirement SystemCalifornia Public Employees Retirement System cut its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 6.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 213,687 shaApril 8, 2025 | marketbeat.comEuropean Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung CancerApril 7, 2025 | prnewswire.comTrexquant Investment LP Invests $6.50 Million in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Trexquant Investment LP bought a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 135,873 shares of the biopharmaceutical company's stock, valued at approximately $6,49April 7, 2025 | marketbeat.comSchroder Investment Management Group Sells 9,933,836 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)Schroder Investment Management Group cut its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 99.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 87,503 shares of the biopharmaceutical compApril 7, 2025 | marketbeat.comOrion Portfolio Solutions LLC Sells 5,041 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)Orion Portfolio Solutions LLC reduced its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 16.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 26,072 shares of the biopharmaceuticalApril 6, 2025 | marketbeat.comLPL Financial LLC Increases Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)LPL Financial LLC grew its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 36.6% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 207,003 shares of the biopharmaceutical company's stock after buying an additional 55,410 shareApril 6, 2025 | marketbeat.comBryce Point Capital LLC Invests $607,000 in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Bryce Point Capital LLC bought a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 12,703 shares of the biopharmaceutical compApril 5, 2025 | marketbeat.comB. Metzler seel. Sohn & Co. AG Sells 10,087 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)B. Metzler seel. Sohn & Co. AG decreased its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 30.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 23,096 shares of the biopharmaceutical company's stApril 5, 2025 | marketbeat.comNorges Bank Takes Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Norges Bank bought a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 1,256,104 shares of the biopharmaceutical company's stock, valApril 5, 2025 | marketbeat.comHeadlands Technologies LLC Takes Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Headlands Technologies LLC bought a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 13,418 shares of the bioApril 4, 2025 | marketbeat.com4,548 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Purchased by Diametric Capital LPDiametric Capital LP purchased a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 4,548 shares of the biopharmaceutical company's stock, valued at appApril 4, 2025 | marketbeat.comInsider Selling: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Sells 503 Shares of StockHalozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) Director Jeffrey William Henderson sold 503 shares of the business's stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $64.05, for a total transaction of $32,217.15. Following the transaction, the director now directly owns 33,108 shares of the company's stock, valued at $2,120,567.40. The trade was a 1.50 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.April 3, 2025 | marketbeat.comAlliancebernstein L.P. Decreases Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Alliancebernstein L.P. decreased its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 10.0% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 3,068,432 shares of the biopharmaceutical company's stock after selling 339,909 shares durinApril 3, 2025 | marketbeat.comArrowstreet Capital Limited Partnership Has $47.47 Million Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Arrowstreet Capital Limited Partnership lifted its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 141.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 992,887 shares of the biopharmaceutical company'sApril 3, 2025 | marketbeat.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Director Sells $32,217.15 in StockApril 2, 2025 | insidertrades.comCorient Private Wealth LLC Sells 14,464 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)Corient Private Wealth LLC lessened its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 71.5% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 5,779 shares of the biopharmaceutical company's stock after sellApril 2, 2025 | marketbeat.comNew Age Alpha Advisors LLC Buys Shares of 28,264 Halozyme Therapeutics, Inc. (NASDAQ:HALO)New Age Alpha Advisors LLC purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 28,264 shares of the biopharmaceutical company's stock, valApril 1, 2025 | marketbeat.comVanguard Group Inc. Boosts Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Vanguard Group Inc. boosted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 3.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 13,281,714 shares of the biopharmaceuticalApril 1, 2025 | marketbeat.comHalozyme: Bristol Myers receives positive CHMP opinion for Opdivo/EnhanzeApril 1, 2025 | markets.businessinsider.comHalozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid Tumor IndicationsMarch 31, 2025 | prnewswire.comKLP Kapitalforvaltning AS Takes Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)KLP Kapitalforvaltning AS bought a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 26,200 shares of the biopharmaceutical company's stock,March 31, 2025 | marketbeat.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Horizon Investment Services LLCHorizon Investment Services LLC lessened its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 83.3% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 4,759 shares of the biopharmaceutical company's stock after selling 23,707 shares during the peMarch 30, 2025 | marketbeat.comEntryPoint Capital LLC Takes Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)EntryPoint Capital LLC acquired a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 4,812 shares of the biopharmaceutical companyMarch 30, 2025 | marketbeat.comPrudential Financial Inc. Lowers Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Prudential Financial Inc. cut its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 3.2% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 223,288 shares of the biopharmaceutical company's stocMarch 30, 2025 | marketbeat.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Stake Lifted by Quantbot Technologies LPQuantbot Technologies LP increased its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 193.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,6March 30, 2025 | marketbeat.comabrdn Healthcare Investors Q4 2024 CommentaryMarch 30, 2025 | seekingalpha.comThrivent Financial for Lutherans Has $1.87 Million Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Thrivent Financial for Lutherans lessened its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 83.2% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 39,206March 30, 2025 | marketbeat.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Rating of "Moderate Buy" by BrokeragesHalozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) has been given an average rating of "Moderate Buy" by the ten research firms that are presently covering the firm, Marketbeat reports. Four research analysts have rated the stock with a hold recommendation and six have issued a buy recommMarch 30, 2025 | marketbeat.comArtisan Partners Limited Partnership Trims Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Artisan Partners Limited Partnership reduced its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 56.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,373,089 shares of theMarch 29, 2025 | marketbeat.comAmerican Century Companies Inc. Acquires 15,079 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)American Century Companies Inc. raised its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 1.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 866,366 shares of the biopharmaceutical cMarch 29, 2025 | marketbeat.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Corebridge Financial Inc.Corebridge Financial Inc. trimmed its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 4.9% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 205,099 shares of the biopharmaceutical company's stock after selling 10,465 shares during tMarch 28, 2025 | marketbeat.comTeacher Retirement System of Texas Acquires 5,594 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)Teacher Retirement System of Texas increased its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 17.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 37,516 shares of the biopharmaceutical company's stock after purcMarch 28, 2025 | marketbeat.comHighTower Advisors LLC Trims Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)HighTower Advisors LLC lowered its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 54.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 16,594 shares of the biopharmaceuticaMarch 28, 2025 | marketbeat.com Remove Ads Get Halozyme Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter. Email Address HALO Media Mentions By Week HALO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HALO News Sentiment▼1.230.86▲Average Medical News Sentiment HALO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HALO Articles This Week▼1910▲HALO Articles Average Week Remove Ads Get Halozyme Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BIIB News Today UTHR News Today INCY News Today BMRN News Today EXEL News Today NBIX News Today EXAS News Today MDGL News Today RGEN News Today ALKS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HALO) was last updated on 4/14/2025 by MarketBeat.com Staff From Our PartnersThe Last Time This Happened, Americans Lost BillionsWall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...Banyan Hill Publishing | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Halozyme Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Halozyme Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy HALO Stock Free HALO Stock Alerts